NCT02670122View on ClinicalTrials.gov

Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC

CompletedOBSERVATIONAL
Enrollment

131

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Hepatocellular Carcinoma
Interventions
DEVICE

DEB-TACE

Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.

Trial Locations (1)

28034

Hospital Ramón y Cajal, Madrid

All Listed Sponsors
lead

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

NCT02670122 - Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC | Biotech Hunter | Biotech Hunter